The Much-Feared FDA Form 483
It’s a powerful tool. Are we using it appropriately?
In this first of three related posts, I’ll be diving into a topic that some may find esoteric, but which I believe it has a significant effect on the efficiency and effectiveness of manufacturing and clinical research. I’ll be examining how the FDA works by taking a close look at a key tool—Form 483—that the agency uses to enforce adherence to quality regulations in the manufacture of FDA-regulated products, as well as research that supports quality, safety, and effectiveness. This series comprises 1) a general discussion of Form 483; 2) the specifics of its use in evidence generation (clinical trials); and 3) the specifics of the proposed use of Form 483 to assess the quality of generic drugs.
As always, I put forward these ideas humbly, recognizing that my opinions may not be on target, but I hope that readers will understand the urgency of working to optimize processes that assure the quality of FDA-regulated products, with an eye to reducing friction and uncertainty. We need to avoid creating systems that add inefficiency to the system with no real benefit and instead focus the quality effort where it can make a difference.
Form 483 is a document peculiar to the world of the FDA. It serves an important purpose in the regulation of everything that the agency oversees: food, drugs, medical devices, biologics, animal health products, cosmetics, tobacco, and more. It’s the means by which an FDA investigator notifies a firm that conditions were observed that may have violated the Food, Drug and Cosmetics Act (the federal law from which the FDA principally derives its regulatory authority).
The form is left with the firm at the end of an inspection, but it is not the FDA’s final agency action. The 483 is a publicly available document that can be found through searching the agency’s FOIA Reading Room. Firms have a chance to respond to the observations documented in the 483 within 15 business days from receipt. This process was recently described for manufacturing facilities in a new FDA draft guidance. As discussed in more detail below, a final resolution of the issues identified in the 483 involves a review of the firm’s response and the views of the relevant agency center about what the findings mean.
For FDA afficionados, Howard Sklamberg, a former FDA official and well-known expert in laws related to the FDA recounted the origins of Form 483:
“Decades ago, industry lobbied for a provision in section 704 of the FDCA - the part governing inspections - that requires written notice of some violations to be given at the end of the inspection. Note it only applies to a small category of violations and not to GCP at all but to be on the safe side, FDA invented the 483 and had it apply to everything.”*
*Howard Sklamberg, personal correspondence, 2026
Over the course of my career, I’ve been on all sides of the 483. As a clinical trialist, while serving as a principal investigator or coordinating center director, I was responsible for the coordination and leadership of multiple clinical trials that underwent FDA inspection. I’ve also been in an institutional leadership role with biological manufacturing reporting to me at an academic medical center. And I’ve been on boards and employed by or consulting with pharmaceutical, device, biotech, and technology industries, all of which were subject to FDA inspections. And of course, as FDA Commissioner, I’ve been on the agency’s side of the equation.
Anyone who has been on the receiving end of an FDA inspection realizes how anxiety-provoking they are.
In an ideal world, firms would constantly plan for comprehensive quality systems and assess the quality of work and product across the entire spectrum of their activities. When deviations from high-quality practices were detected, or a defect in the quality of a product was observed, an investigation would occur, a plan would be specified, and corrective action would be taken, after which the quality system would be updated. The need for a federal organization that assesses the quality of product manufacturing and distribution and the evidence that’s required for a firm to receive approval for marketing and advertising of an FDA-regulated product speaks to the fact that the entire process is complicated, imperfect, and consequential.
Anyone who has been on the receiving end of an FDA inspection realizes how anxiety-provoking they are. Given human imperfections and the uncertainties involved, a firm is always concerned that a minor error or infraction could lead to a cascade of negative events that wind up impeding the mission of company or institution or jeopardizing its financial well-being and reputation.
When I first arrived at the FDA in 2015 as Deputy Commissioner for Medical Products and Tobacco, the processes by which inspections were conducted and their findings acted upon were mysteries to me. I would learn that it was a complex system that had evolved over many decades, dating back to the origins of the FDA. In the agency’s early days, it did not have a central organization but operated as a federation of regional field offices with a common mission, mostly oriented towards “in the field” inspections and investigations.
The FDA’s central organization developed along with other federal agencies, originally in the infamous Parklawn Building (I can still smell the cigarettes from smokers outside the building) in suburban Washington and then moving to the amazing White Oak campus (more like a university campus than an old-fashioned government building). Despite the well-known importance of FDA’s product centers (drugs, devices, biologics, food, veterinary medicine), the relationship between the organization that conducts inspections and investigations (previously the Office of Regulatory Affairs [ORA], recently changed to the Office of Inspections and Investigations [OII]) and the product centers was always in a state of tension.
The system for resolving quality issues involved management silos. Inspection results would be written up and reviewed up the line of command within ORA. Findings would then be forwarded “over the transom” to the relevant product center for final adjudication. Differences were reviewed and resolved in leadership meetings, but months might go by with the only available record of the inspection being the investigator’s report. Such gaps could give rise to situations in which a 483 would be in place at the manufacturing facility or research site while the final interpretation was in limbo for months. During my second term, Principal Deputy Commissioner Janet Woodcock led the charge to consolidate quality efforts across product Centers and ORA/OII to improve the efficiency of the process.
Unfortunately, the issuance of a Form 483 is in my opinion too often used as a proxy for overall quality of the firm to which it is issued rather than being understood as a tool for quality improvement that signifies the need for attention to an issue or set of issues. The recent FDA guidance emphasizes again that Form 483 is not a final FDA action (something that involves many contextual factors), and that in the response to the 483 the firm has the opportunity to resolve differences of opinion with the investigator and FDA team responsible for the inspection. Thus, using the 483 alone as a surrogate for overall quality could be very misleading. This will be discussed in more detail in the next two installments.
The FDA job title in this context is “investigator” rather than “inspector,” reflecting the difficulty of the task and the degree of professionalism required. These professionals have a tough job, one that requires them to engage with enormously complex manufacturing and clinical trial operations being directed by highly qualified experts. It takes courage to walk into a facility knowing both the power and responsibility you have, as well as the concerns of those whom you are inspecting. This is especially salient in foreign inspections, in which case the FDA investigator is literally going into a foreign facility, sometimes in a country that may not be on the best terms with the U.S. government. It’s also true that an individual investigator or small investigative team can’t know everything about the context of the firm. In the future, the broad capabilities of AI applications to ingest, aggregate, and synthesize information from disparate sources should help investigators make the best possible use of their time and to place a physical inspection in context.
In summary, the concept of identifying problems and correcting them in an explicit manner is a key component of modern quality systems. The unfortunate use of Form 483 as an isolated proxy for making blanket decisions about the overall quality of work does not serve this interest. However, using it properly - as a tool to spur improvement in the quality of manufacturing and research and development - is to be encouraged. The special situations of clinical trials and manufacturing facilities should be evaluated in more detail to optimize the use of inspections and quality assessment of trials, allowing us to generate more high-quality evidence in a more efficient manner.
In the next two installments, I’ll discuss the role of Form 483 in research and evidence generation and its role in evaluation of the quality of generic drug manufacturing. You can also find further discussion of these issues in an interview available here.
The point of GXP inspections is that because you are regulated industry “big brother is watching.” My observation over decades is that when companies sense the government is taking its foot off the pedal by being less strict or conducting fewer inspections there is a greater willingness to cut corners. This often translates into short-term gains but long-term losses, as those who go too far in cutting corners more often than not end up facing serious consequences.
Thank you for your perspective and documenting the history, purpose, and how things are supposed to work. This information will help those who will be putting humpty dumpty back together again. I hope they are listening.